EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy

Liyang Ji, Prabuddha Waduge, Yan Wu, Chengchi Huang, Avinash Kaur, Paola Oliveira, Hong Tian, Jinsong Zhang, J Timothy Stout, Christina Y Weng, Keith A Webster, Wei Li iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Liyang Ji und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH, American Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR), a leading cause of vision loss in working-age adults, induces mosaic patterns of vasculopathy that may be associated with spatial heterogeneity of intraretinal endothelial cells. We recently reported that secretogranin III (Scg3), a neuron-derived angiogenic and vascular leakage factor, selectively binds retinal vessels of diabetic but not healthy mice. Here, we investigated endothelial heterogeneity of three retinal vascular plexuses in DR pathogenesis and the therapeutic implications. Our unique in vivo ligand binding assay detected a 22.7-fold increase in Scg3 binding to retinal vessels of diabetic mice relative to healthy mice. Functional immunohistochemistry revealed that Scg3 predominantly binds to the DR-stressed CD31− deep retinal vascular plexus but not to the relatively healthy CD31+ superficial and intermediate plexuses within the same diabetic retina. In contrast, VEGF bound to healthy and diabetic retinal vessels indiscriminately with low activity. FITC-dextran assays indicated that selectively increased retinal vascular leakage coincides with Scg3 binding in diabetic mice that was independent of VEGF, whereas VEGF-induced leakage did not distinguish between diabetic and healthy mice. Dose–response curves showed that the anti-Scg3 humanized antibody (hAb) and anti-VEGF aflibercept alleviated DR leakage with equivalent efficacies, and that the combination acted synergistically. These findings suggest: (i) the deep plexus is highly sensitive to DR; (ii) Scg3 binding to the DR deep plexus coincides with the loss of CD31 and compromised endothelial junctions; (iii) anti-Scg3 hAb alleviates vascular leakage by selectively targeting the DR-stressed deep plexus within the same diabetic retina; (iv) combined anti-Scg3 and anti-VEGF treatments synergistically ameliorate DR through distinct mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyDiabetes Mellitus, ExperimentalAnimalsMiceEndothelial CellsRetinaRetinal VesselsChromogranins

Stichwörter der Autor:innen

Scg3VEGFdiabetic retinopathydisease-targeted anti-angiogenic therapyendothelial heterogeneitysynergistic combination anti-angiogenic therapy

Substanzen

secretogranin IIIChromogranins

Autor:innen und Institutionen

  • Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL 33136, USA.
  • Everglades Biopharma, LLC, Houston, TX 77098, USA.
  • Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110005, China.

ORCID-Profile: Wei Li

Förderung

  • NEI NIH HHS
  • NIH
  • American Diabetes Association
  • Knights Templar Eye Foundation Endowment in Ophthalmology
  • Research to Prevent Blindness (RPB)

Zitieren

APA

Ji, L., Waduge, P., Wu, Y., Huang, C., Kaur, A., Oliveira, P., Tian, H., Zhang, J., Stout, J. T., Weng, C. Y., Webster, K. A., & Li, W. (2023). Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310531

Vancouver

Ji L, Waduge P, Wu Y, Huang C, Kaur A, Oliveira P, et al. Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310531

BibTeX
@article{Ji2023,
  author = {Ji, Liyang and Waduge, Prabuddha and Wu, Yan and Huang, Chengchi and Kaur, Avinash and Oliveira, Paola and Tian, Hong and Zhang, Jinsong and Stout, J Timothy and Weng, Christina Y and Webster, Keith A and Li, Wei},
  title = {Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310531}
}
Kostenlos starten →